Deep sequencing analysis of microRNA expression in human melanocyte and melanoma cell lines

Ding, Nan; Wang, Shaobin; Yang, Qiong; Li, Yongjun; Cheng, Hua; Wang, Junyun; Wang, Dong; Deng, Yongbo; Yang, Yadong; Hu, Songnian; Zhao, Hua; Fang, Xiangdong

doi:10.1016/j.gene.2015.07.013

Cited by 15 publications

(12 citation statements)

References 43 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unsupervised hierarchical clustering of filtered gene expression profiles (FPKM >1) was performed using R software to examine relationships between the three samples [41]. The distance ( d XY ) between genes and samples was evaluated using the Pearson correlation coefficient ( r XY ), where d XY = 1 − r XY .…”

Section: Methodsmentioning

confidence: 99%

Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis

Ding

Zhang

Yang

et al. 2017

Genomics, Proteomics &Amp; Bioinformatics

Self Cite

View full text Add to dashboard Cite

Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder in human bone marrow. Over 50% of patients with myelofibrosis have mutations in JAK2, MPL, or CALR. However, these mutations are rarely detected in children, suggesting a difference in the pathogenesis of childhood PMF. In this study, we investigated the response to drug treatment of a monozygotic twin pair with typical childhood PMF. The twin exhibited different clinical outcomes despite following the same treatment regimen. The transcriptomic profiles of patient samples after drug treatment (E2 and Y2) were significantly different between the twin pair, which is consistent with the observation that the drug treatment was effective only in the younger brother, despite the twin being genetically identical. Bioinformatics analysis of the drug-responsive genes showed that the JAK-STAT pathway was activated in the cured younger brother, which is opposite to the pathway inhibition observed in adult PMF cases following treatment. Moreover, apoptosis and cell cycle processes were both significantly influenced by drug treatment in the sample of younger brother (Y2), implying their potential association with the pathogenesis of childhood PMF. Gene mutations in JAK2, MPL, or CALR were not observed; however, mutations in genes including SRSF2 and SF3B1 occurred in this twin pair with childhood PMF. Gene fusion events were extensively screened in the twin pair samples and the occurrence of IGLV2-14-IGLL5 gene fusion was confirmed. The current study reported at transcriptomic level the different responses of monozygotic twin brothers with childhood PMF to the same androgen/prednisone treatment regimen providing new insights into the potential pathogenesis of childhood PMF for further research and clinical applications.

show abstract

Section: Methodsmentioning

confidence: 99%

Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis

Ding

Zhang

Yang

et al. 2017

Genomics, Proteomics &Amp; Bioinformatics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many studies revealed that the expression of several miRNAs is deregulated in melanoma cells and that aberrant miRNA expression is undoubtedly linked to important processes affecting tumor formation and progression [35,36,[84][85][86][87][88][89][90][91]. One example are members of the let-7 miRNA family which are involved in melanoma invasiveness [92], cell cycle promotion [93] and metabolism [94].…”

Section: The Role Of Mirnas In Melanoma and Hepatocellular Carcinomamentioning

confidence: 99%

“…As comprehensively depicted above, one single miRNA can regulate multiple targets [15,88,91,311]. Systemic inhibition of a defined miRNA in melanoma or HCC patients could therefore also lead to adverse side effects.…”

Section: Therapeutic Targeting Of Mirnas and Mirna-pathwaysmentioning

confidence: 99%

“…Further risk factors for melanoma development are family predisposition [80] as well as multiple occurrences of melanocytic nevi (which are benign proliferations of melanocytes in the skin and can be transformed to precursor lesions of melanoma) [81]. In advanced/metastatic disease, systemic first-line therapeutic options are specific BRAF-inhibitors for BRAF V600E -mutated melanomas [82] as well as immune checkpoint inhibitors [83] but the understanding of emergence of acquired resistance to these therapies is still an unmet clinical need.Many studies revealed that the expression of several miRNAs is deregulated in melanoma cells and that aberrant miRNA expression is undoubtedly linked to important processes affecting tumor formation and progression [35,36,[84][85][86][87][88][89][90][91]. One example are members of the let-7 miRNA family which are involved in melanoma invasiveness [92], cell cycle promotion [93] and metabolism [94].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

Linck-Paulus

Hellerbrand

Bosserhoff

et al. 2020

Cells

View full text Add to dashboard Cite

In this review, we summarize the current knowledge on miRNAs as therapeutic targets in two cancer types that were frequently described to be driven by miRNAs—melanoma and hepatocellular carcinoma (HCC). By focusing on common microRNAs and associated pathways in these—at first sight—dissimilar cancer types, we aim at revealing similar molecular mechanisms that are evolved in microRNA-biology to drive cancer progression. Thereby, we also want to outlay potential novel therapeutic strategies. After providing a brief introduction to general miRNA biology and basic information about HCC and melanoma, this review depicts prominent examples of potent oncomiRs and tumor-suppressor miRNAs, which have been proven to drive diverse cancer types including melanoma and HCC. To develop and apply miRNA-based therapeutics for cancer treatment in the future, it is essential to understand how miRNA dysregulation evolves during malignant transformation. Therefore, we highlight important aspects such as genetic alterations, miRNA editing and transcriptional regulation based on concrete examples. Furthermore, we expand our illustration by focusing on miRNA-associated proteins as well as other regulators of miRNAs which could also provide therapeutic targets. Finally, design and delivery strategies of miRNA-associated therapeutic agents as well as potential drawbacks are discussed to address the question of how miRNAs might contribute to cancer therapy in the future.

show abstract

“…В свою очередь, молекулы микроРНК могут как свободно находиться в плазме крови, так и быть в составе экзосом, микровезикул размерами 30-120 нм, участвующих в межклеточном взаимодействии. В ряде исследований было доказано содержание микроРНК в экзосомах, а также их способность при такой форме доставки влиять на фи зиологию клеток -реципиентов экзосом [39].…”

Section: биология микрорнкunclassified

MicroRNA expression in melanocytes and melanoma cells

Petkevich

Шубина

Abramov

et al. 2018

Rossijskij bioterapevtičeskij žurnal

View full text Add to dashboard Cite

Diagnostic biomarkers cancer diagnostics at preclinical stage seem to be a very promising strategy to increase effectiveness of anti-cancer treatment. Currently there are no such biomarkers available for daily routine practice. However, there are some candidate molecules in research that possibly can be used as biomarkers for early diagnosis, one of them is microRNA. MicroRNA is a small, 20–25 bp, non-coding RNA that is highly involved into epigenetic regulation of gene expression. These molecules participate in malignant transformation of normal cells into cancer cells including melanoma. And moreover, definite expression level of some microRNAs are essential for normal differentiation and function of human cells. Changes in microRNA profile are one of the reasons for malignant tumor development. Identification of these changes may help to develop diagnostic systems to start anti-cancer treatment at early stages.

show abstract

Deep sequencing analysis of microRNA expression in human melanocyte and melanoma cell lines

Cited by 15 publications

References 43 publications

Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis

Transcriptome Analysis of Monozygotic Twin Brothers with Childhood Primary Myelofibrosis

Dissimilar Appearances Are Deceptive–Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma

MicroRNA expression in melanocytes and melanoma cells

Contact Info

Product

Resources

About